Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Muncie, IN (PRWEB) May 27, 2015 The ... public to join in celebrating National Model Aviation Day. The ... Aviation Day was created to celebrate the model aviation hobby ... AMA encourages all of its approximately 2,350 chartered clubs to ... hosting an event in their communities. There will also be ...
(Date:5/27/2015)... , May 27, 2015 /CNW/ - CQDM, Brain ... close to $8.5M to six (6) multi-disciplinary and multi-provincial ... neuroscience within their Focus on Brain strategic initiative. To ... entities involved as in-kind contributions. This exciting announcement was ... Association for Neuroscience in the presence of Inez Jabalpurwala, ...
(Date:5/27/2015)... 27, 2015 The ALS Therapy ... its wholly owned subsidiary, Anelixis Therapeutics , $1.5 ... ALS that targets the innate immune system. The funding ... Institute received from the 2014 social media phenomenon known ... of $4 million raised directly by the Institute through ...
(Date:5/27/2015)... , May 27, 2015  CytomX, a ... of cancer, today announced the appointments of ... Cynthia Ladd as senior vice president ... was chief financial officer of Onyx Pharmaceuticals, an ... independent consultant and legal counsel to several leading ...
Breaking Biology Technology:Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3
... ... Technology Platform for Life Sciences Marketing, R&D and Medical Affairs , ... Charlottesville, VA, San Diego, CA, New ... for information and research for life sciences marketing, compliance, R&D and medical affairs announces ...
... , , , ... the launch of QIAGEN,s new QIAsafe DNA Blood Products, the first ... SampleMatrix(R) technology. , , The QIAsafe DNA Blood ... management chain. Biomatrica,s SampleMatrix technology significantly simplifies transport and storage of ...
... RANCHO CORDOVA, Calif., Sept. 9 ThermoGenesis Corp. (Nasdaq: ... and storing adult stem cells, today reported results for the fourth ... For the quarter ended June 30, 2009, the Company reported revenues ... the fourth quarter a year ago. As the Company indicated previously, ...
Cached Biology Technology:OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm 2OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm 3QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 2QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 3QIAGEN's New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatrica's SampleMatrix(R) Technology 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 3ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 5ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 6ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 7ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 8ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 9ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 10
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Siglec-9 Biotinylated Affinity Purified Pab...
Biology Products: